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mortality (reduced life expectancy of PFO carriers) has to be held 
accountable for that. In most individuals, a PFO will remain asymp-
tomatic for life. However, since the initial blaming of a fatal stroke 
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INTRODUCTION 
Stroke remains the third leading cause of mortality and the most 
important cause of serious, long-term disability.(1) Most strokes are 
of ischaemic origin. Atherosclerosis plays a causative role as do 
other factors that vary among countries, genders, lifestyles, and a 
number of well documented risk factors.(2) In the United States of 
America it is estimated that almost 90% of the roughly 800 000 
strokes per year are ischaemic.(3) Cardioembolic reasons account 
for 19% and carotid disease for 15% of them. A patent foramen 
ovale (PFO) is per se not yet considered a primary cause for stroke. 
It is subsumed under the 36% of strokes labelled cryptogenic. This 
article summarises the current evidence for percutaneous PFO 
closure for secondary prevention of cerebrovascular events.
PATENT FORAMEN OVALE
Autopsy studies revealed that the foramen ovale remains dynam-
ically patent in approximately 1/4th of the general population.(4) 
A PFO thus represents the most common cardiac congenital 
abnormality (Figure 1). It permits intracardiac shunting while right 
atrial pressure exceeds left atrial pressure (Figure 2). A PFO 
accounts for up to 95% of right-to-left shunts. Pulmonary shunts 
account for about 4% and atrial septal defects for less than 1%.
The prevalence of PFO declines from 34% during the first three 
decades of life, to 25% for the 4th to 8th decade, and to 20% 
beyond that.(4) Spontaneous closure even late in life or selective 
Stroke is the most debilitating cardiovascular event. It has a 
variety of causes that may be present simultaneously. In 
young or otherwise healthy people a patent foramen ovale 
(PFO) is increasingly searched for. In stroke of the elderly 
atherosclerosis and atrial fi brillation are in the foreground 
but the PFO should not be ignored. The risk of a PFO 
related stroke over time is controversial and so is its pre-
vention by PFO closure. Percutaneous PFO closure is a 
minimally invasive procedure which can be performed with 
high success and low morbidity. We review the rationale 
for PFO closure for secondary prevention of embolic events. 
SAHeart 2014;11:18-27
FIGURE 1: Patent foramen ovale (PFO) seen from the left atrium. 
The fl ap-like septum primum (SP) can move away from the solid 
septum secundum (SS) thereby allowing an interatrial shunt.
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in a young woman to a PFO by Cohnheim in 1877, an underlying 
PFO has been increasingly recognised as potential mediator of 
systemic embolism, particularly in conjunction with an atrial septal 
aneurysm (ASA).(5-12)
ASA is a congenital abnormality of the interatrial septum charac-
terised by a redundant, central part of the septum primum (Figures 
1 and 2). The prevalence of an ASA in the general population 
was about 1% in autopsy series(6,13,14) and 2.2% in a population-
based transoesophageal echocardiographic (TOE) study.(7) ASA 
is associated with a PFO in 50% - 85% of cases(6-8) and likely co-
responsible for it. The constant motion of the ASA inhibits post-
natal fusion and thus begets the PFO. The criteria for distinction 
between a floppy interatrial septum and ASA vary between 
autopsy, transthoracic echocardiography (TTE), and TOE. ASA is 
generally diagnosed if the diameter of the base of the flimsy por-
tion of the interatrial septum exceeds 15mm and the excursion of 
the aneurysmal membrane is ≥10mm in either left or right atrium, 
or if the sum of the total excursion is ≥10mm.(6)
ASA has been associated with cerebral ischaemic events in 
numerous case-control studies.(6-12) The combination of a PFO and 
ASA constitutes a particularly high risk situation with a relative risk 
of 16 (95% CI 3-86) comparing ischaemic stroke with non-stroke 
control subjects, and a relative risk of 17 (95% CI 2-134) comparing 
cryptogenic stroke with known stroke case control subjects (age 
<55 years).(5) ASA may facilitate paradoxical embolism by leading 
to a more frequent and wider opening of the PFO channel(15) or 
by promoting a right-to-left shunt by redirecting flow from the 
inferior vena cava towards the PFO. 
PFO AND STROKE
In younger patients a classical aetiology is not found in up to 40% of 
ischaemic strokes despite an extensive diagnostic evaluation.(16,17) 
Such strokes are then referred to as cryptogenic, an obvious 
misnomer in the presence of a PFO. Despite the prevalence of 
around 25% of a PFO in the general population,(4) paradoxical 
embolism is rare and typically assumed rather than proven.(18) 
However, the latter holds true equally for strokes attributed to 
atrial fibrillation, prior myocardial infarction, or proximal arterial 
plaques.
The association of PFO with cryptogenic stroke, prominently 
documented in 1988,(19,20) as well as numerous case reports 
depicting a thrombus straddling the PFO, establish paradoxical 
embolism as underlying mechanism. This is corroborated by an 
observational study of 139 patients suffering from major pulmonary 
embolism.(21) Patients with PFO were more likely to die (44% vs. 
13%, P=0.02) or to suffer a stroke (13% vs. 2%, P=0.02) or 
peripheral embolism (15% vs. 0%, P=0.01) in the presence of a 
PFO. The PFO constituted an independent predictor of mortality. 
The higher frequency of pelvic vein thrombosis at magnetic reso-
nance (MR) venograms within 2 days of the onset of symptoms in 
stroke patients with PFO (20%) than with conventional stroke 
causes (4%) again points to paradoxical embolism via PFO.(22) So do 
an observational study of 202 patients with transvenous pacing 
leads, in whom the presence of intracardiac shunts was associated 
with a >2-fold increased risk of systemic embolism during long-
term follow-up,(23) and a large Danish population based study on 
patients with deep venous thrombosis (n=25,199) or pulmonary 
embolism (n=16,925). Their relative risks of stroke during the first 
year after the thrombotic event were 2.2 (1.9-2.6) and 2.9 (2.3-3.7) 
fold increased compared with controls (n=163,566).(24)
PFO AND FIRST ISCHAEMIC STROKE
In the European population, the annual incidence of a first ischaemic 
stroke is 139 per 100 000 inhabitants.(25) Since around 60% of 
these events can be attributed to conventional causes,(16,17) the 
annual risk attributed to paradoxical embolism has been estimated 
at 28 per 100 000 persons with a PFO per year.(26) The association 
of PFO with cryptogenic stroke has been repeatedly confirmed.(5,27) 
This observation has been extended to adults >55 years, with a 
significantly higher prevalence of PFO alone (28.3% vs. 11.9%; OR 
FIGURE 2: Angiographic depiction of a patent foramen ovale (PFO) 
at the end of a Valsalva manoeuvre with contrast medium passage from 
the right atrium (RA) to the left atrium (LA) during temporary 
separation of the mobile septum primum (SP) from the robust septum 
secundum (SS). The insert shows a 25mm Amplatzer PFO Occluder in 
the PFO (left anterior oblique projection).
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2.9; 95% CI 1.7 to 5.0; p<0.001) as well as of PFO associated with 
ASA (15.2% vs. 4.4%; OR 3.9; 95% CI 1.8 to 8.5; p<0.001) among 
patients with cryptogenic stroke compared to those with con-
ventional stroke causes.(28) A meta-analysis of 23 case-control 
studies, suggested that the odds of having a PFO were 2.9 times 
higher in patients with cryptogenic stroke when compared to 
controls (95% CI, 2.1 to 4.0).(29)
In contrast, 2 prospective population-based studies failed to confirm 
PFO as an independent risk factor for cryptogenic stroke,(30,31) with 
only a nonsignificant trend towards a higher incidence of stroke 
in persons with PFO. The Olmsted County study enrolled 588 
randomly selected subjects.(30) PFO was identified using TTE in 24% 
and an ASA in 2%. During a mean follow-up of 5.1 years, cere-
brovascular events (cerebrovascular death, ischaemic stroke, and 
TIA) had occurred in 41 subjects (7%). After adjustment for age 
and comorbidities, PFO was not an independent predictor of 
stroke (HR 1.46; 95% CI 0.74-2.88; p=0.28). The risk of stroke 
among subjects with ASA was almost four times greater than in 
those without, but proportional hazard regression analysis did 
not establish statistical significance (HR 3.72; 95% CI 0.88-15.71; 
p=0.074). The relatively small sample size and the advanced age 
(mean 67 years) of the study participants were criticised, in addi-
tion to the inadequate screening sensitivity resulting in a signifi-
cant percentage of undetected PFOs.
Among the 1 100 participants of the Northern Manhattan study,(31) 
TTE detected a PFO in only 15% and an ASA in 3%. During 6.6 
years of follow-up, 68 subjects suffered an ischaemic stroke (6%). 
After adjustment for demographic and risk factors, PFO was not 
significantly associated with stroke (HR 1.64; 95% CI 0.87-3.09). 
Isolated ASA was associated with an elevated stroke incidence (HR 
3.66; 95% CI 0.88-15.30), but ASA associated with PFO was not 
(HR 1.25; 95% CI 0.17-9.24). The low prevalence of PFO as 
compared to autopsy studies confirms TTE as not sensitive enough 
to screen for a PFO.
PFO AND RECURRENT CEREBROVASCULAR 
EVENTS
The natural history after cerebrovascular events in patients with 
PFO remains insufficiently defined. This is problematic since the risk 
of recurrence determines the therapeutic value of interventions 
aimed at secondary prevention. Traditionally, most patients with 
presumed paradoxical embolism are treated with antithrombotic 
medications. Data are scarce concerning the efficacy of oral anti-
coagulation as opposed to antiplatelet agents, and the duration of 
treatment required. Observational studies on medical treatment in 
patients with PFO with either antiplatelet agents or coumarin 
reported a risk of recurrent stroke or TIA ranging from 3% - 12% 
during the first year.(10,11,27,32-34) Both larger PFO size(15,17,35,36) and a 
greater degree of right-to-left shunt(15,32,35,37) signify a higher risk 
for paradoxical embolism. However, there are major differences 
in the baseline characteristics of the patient populations studied, 
which may account for the disparate recurrence rates reported. 
According to a meta-analysis of 15 studies of medical treatment 
in 2 548 patients with cryptogenic cerebrovascular events, the 
pooled rate of recurrent ischaemic stroke or TIA was 4.0 events 
per 100 patient-years (95% CI, 3.0-5.1) while the rate of recur-
rent ischaemic stroke was 1.6 events per 100 patient-years (95% 
CI, 1.1-2.1).(38) Of note, in trials with antiplatelet agents or oral 
anticoagulation, the risk of recurrence appeared lower with the 
latter. Although medical treatment lacks the risk of interventional 
procedures, it is associated with other adverse effects, most notably 
an increased risk of bleeding. Thus, major bleeding amounted to 
1.5-2.2 per 100 patient years in the prospective PFO in crypto-
genic stroke study (PICSS),(27) a subanalysis of the Warfarin-Aspirin 
Recurrent Stroke Study (WARSS),(39) with a marked but not signi-
ficant difference showing poorer protection with acetylsalicylic acid 
than with oral anticoagulation. Treatment with acetylsalicylic acid 
has also been found suboptimal in patients with PFO and associated 
ASA.(8,11) Another important limitation of medical treatment is lack 
of compliance. 
PERCUTANEOUS PFO CLOSURE
Percutaneous (device) closure of the PFO has supplanted surgical 
PFO closure and constitutes an alternative treatment. It eliminates 
the pathway for paradoxical embolism, and may thus circumvent 
the need for long-term blood thinners. However, it is associated 
with a small periprocedural risk and significant costs, both for the 
device (about 3 000 USD, according to regional markets) and the 
procedure.
Bridges, et al. introduced percutaneous PFO closure in 1992 to 
reduce the incidence of recurrent strokes.(40) Percutaneous PFO 
closure has been shown safe and feasible in numerous studies, 
using a variety of devices.(41-52) Figure 3 depicts the gold standard 
Amplatzer PFO Occluder with clinically approved offsprings. The 
reported success rates varied between 90 - 100%, with complication 
rates between 0 - 10%. Complete PFO closure was reported in 
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Figulla PFO Occluder Cera Occluder Cocoon Occluder Hyperion Occluder
51 - 100% of patients, and yearly recurrence rates of ischaemic 
strokes and TIAs varied between 0 and 3.4%.
Patients typically undergo TOE prior to the intervention for initial 
diagnosis of PFO and detailed delineation of anatomy, i.e. associ-
ated ASA or Eustachian valve (Figure 4), as well as assessment of 
right-to-left shunt. The procedure can be performed on an out-
patient basis under local anaesthesia and may take less than 30 
minutes.(52) Patients can be released to unrestricted physical activity 
as early as a few hours after the intervention. Antibiotics during 
the intervention are commonplace and prophylaxis against endo-
carditis is recommended for a few months until the device is 
completely covered by tissue. Failed implantation due to inability 
to canulate the PFO is extremely rare (<1%). Periprocedural 
complications have fallen below 1% in experienced centres, and 
complete closure rates of >90% can be expected.(52) Follow-up 
treatment includes acetylsalicylic acid (80 - 300mg daily) for 1 - 6 
months, with the addition of clopidogrel (75mg daily) for 1 - 6 
months at some centres. At 3 - 6 months after percutaneous 
PFO closure, a contrast TOE should be repeated, to assess for 
residual shunt following endothelial overgrowth and exclude 
thrombosis of the device. Transcranial Doppler (TCD) constitutes 
an alternative. However, it cannot rule out a thrombus on the 
device. If the PFO proves completely closed, all medication can 
be discontinued, unless required for another indication, e.g. associ-
ated coronary artery disease.(53) In case of persistence of a moder-
ate or large residual shunt, implantation of a second device is 
recommended, which results in complete closure in approximately 
90% of cases.(52) 
Complications consist mostly of rare arterio-venous fistulae at 
the groin and are device and technique related.(48,51,54) The same 
holds true for residual shunts and thrombus formation.(55) Erosions 
of the free atrial wall, more a threat with the larger devices used 
FIGURE 3: Market leading Amplatzer PFO Occluder with a number of make-alikes that are clinically used. Manufacturers are indicated below the 
respective pictures.
OccluTechTM PFO Lifetech Scientific Vascular Innovations Comed
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for atrial septal defect closure, device endocarditis, or need for 
surgical explantation are exceedingly rare. Long term safety is of 
the utmost importance for a preventive procedure against a low 
risk in natural history. Rarely, supraventricular arrhythmias can be 
induced or triggered by the device leading to the need for 
anticoagulation or left atrial ablation. Transseptal puncture (for later 
left atrial interventions) is not impeded after device implantation 
but rather optically facilitated(56) (Figure 5).
COMPARISON OF MEDICAL TREATMENT 
WITH PFO CLOSURE
Available evidence of studies assessing medical treatment and 
percutaneous PFO closure encompass multiple observational single 
arm studies, 2 comparative registries,(57,58) a systematic review of 
case series, a propensity score matched study(59) and 3 prospective, 
randomised clinical trials (CLOSURE I, PC, RESPECT). Wöhrle(60) 
and Agarwal, et al.(61) summarised clinical outcomes from 15 studies 
with medically treated patients and 12 studies with patients who 
underwent percutaneous PFO closure. The annual rate of stroke or 
TIA was significantly lower after percutaneous PFO closure 
compared with medical treatment and was comparable to event 
rates of patients without PFO.
In a study on long term follow up (median 9 years) in non-
randomised, but propensity matched cohorts (closure vs. medical 
therapy),(59) the primary composite outcome (stroke, TIA, or 
peripheral embolism) occurred in 11% of patients slated to PFO 
closure and 21% of patients slated to medical treatment (HR 0.43; 
95% CI 0.20-0.94; P=0.033). The treatment effect was driven by 
a decrease in the risk of TIA of 5% versus 14%, respectively 
(HR 0.31; 95% CI 0.10-0.94; P=0.039). Mortality was significantly 
reduced when comparing the time periods after device closure 
to those before or without device closure.
The first randomised trial comparing the valve of PFO closure to 
medical therapy for stroke prevention, CLOSURE I (Prospective, 
Multicenter, Randomised Controlled Trial to Evaluate the Safety 
and Efficacy of the STARFlex Septal Closure System Versus Best 
FIGURE 4: Angiographic depiction of an atrial septal aneurysm 
(ASA) of the septum primum (dotted line) combined with a Eustachian 
valve (EV). 
Amplatzer 25mm PFO Occluder depicted in a left anterior oblique 
projection in a patient with an atrial septal aneurysm (ASA) combined 
with a Eustachian valve (EV). The EV divides the right atrium into an 
upper right atrium (URA) and a lower right atrium (LRA). Both ASA 
and EV are likely to maintain the foramen ovale patent and the EV 
guides all potential clots from the lower body directly onto the PFO.
PFO = patent foramen ovale, SS = septum secundum.
FIGURE 5: Place of safe transseptal puncture in the thin-wall septum 
primum (dotted line) caudal to a previously implanted Amplatzer 
25mm PFO Occluder, depicted in a left anterior oblique projection 
showing the device in perfect profi le.
PFO = patent foramen ovale, SS = septum secundum.
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Medical Therapy in Patients with a Stroke of Transient Ischaemic 
Attack due to Presumed Paradoxical Embolism through a Patent 
Foramen Ovale), showed no significant benefit.(62) It was limited 
to 2 years of follow-up and used the obsolete STARFlex device 
since withdrawn. Patients ≤60 years old with a PFO and cryptogenic 
stroke or TIA were randomly assigned either to device closure 
(n=447) or to medical therapy (n=462). Patients in the device 
group were treated with the STARFlex PFO closure device and 
received acetylsalicylic plus clopidogrel for 6 months followed by 
acetylsalicylic alone. Those in the medical therapy group were 
treated with acetylsalicylic, warfarin, or both. The primary endpoint 
was a composite of stroke or TIA at 2 years plus 30 day mortality 
and neurologic mortality beyond 30 days. By intention-to-treat 
analysis, there was no significant difference between device closure 
and medical therapy in the rates of the primary endpoint (5.5% vs. 
6.8%, HR 0.78, 95% CI 0.45-1.35), stroke (2.9% vs. 3.1%), or TIA 
(3.1% vs. 4.1%). Results were similar by per-protocol analysis. Major 
vascular complications were significantly more frequent with device 
closure (3.2% vs. 0%), as was atrial fibrillation (5.7% versus 0.7%, 
most of which was periprocedural or within the first 2 weeks). 
However, over a quarter of index events in CLOSURE I were TIAs 
as were more than half of the outcome events. Fewer than two 
thirds of the baseline MR scans showed acute stroke. Without 
imaging confirmation, a trial of secondary stroke prevention 
becomes heavily dependent on the clinical judgment of individual 
investigators. Including patients with neurological symptoms that 
were not caused by ischaemia, cryptogenic or otherwise, would be 
a mistake. It would lower the outcome rate of recurrent stroke. 
But confusingly it may increase the rate of recurrent neurological 
events that are interpreted as TIA but which are actually due to 
migraine, seizure, or other mechanisms. Moreover, concerns about 
the performance of the STARflex occluder were prominent enough 
in Bern that its use was abandoned a decade ago. Inferior device 
performance might explain why the incidence of the primary 
endpoint was barely different in the 2 treatment groups. Procedural 
success, defined by the protocol as “implantation of 1 or more 
devices during the index procedure with no procedural com-
plications,” was achieved in 89%, i.e. failed in over 10% of 
procedures. Effective closure was assessed at 6 months with a 
surveillance TOE. This required procedural success and a residual 
shunt across the PFO of grade 0 or 1. This benchmark of effective 
closure was met in only 86%, representing a closure rate that is 
below what has been reported with contemporary devices such 
as the Amplatzer PFO Occluder.(52) It should be noted that 
according to the CLOSURE I protocol, a shunt of grade 1 could 
be part of a successful procedural outcome and was also an 
inclusion criterion sufficient to be enrolled into the study. Indeed, 
of the 909 subjects in the study 428 (47%) had a trace shunt of 
1 - 10 bubbles at baseline. Atrial fibrillation was seen during 
follow-up in 9 of the 362 subjects (2.4%) with a device implanted 
as compared to 3 of the 462 medically treated patients (0.6%). 
Atrial fibrillation represents a proven stroke aetiology. It would be 
unfortunate if PFO closure after successfully obliterating the con-
duit for paradoxical embolism introduced another important 
stroke mechanism. Some of these patients had probably already 
suffered from undetected paroxysmal atrial fibrillation at baseline 
but the difference between the groups strongly suggests a signifi-
cant arrhythmogenic potential from the device, at least early on. 
Of considerable concern is the incidence of thrombus formation 
on the device. An earlier study reported a thrombus rate of 
5% - 7% using the STARflex device,(55,63) which is higher than the 
1.1% reported during CLOSURE I. But 1.1% is still high when 
compared to other available devices (0% for the Amplatzer PFO 
Occluder and 0.5% with the Gore Helex Device).(63) Since 
endothelialisation is not complete for several weeks, left-sided 
thrombus formation may explain recurrent events especially in 
the early period after device implantation. PFO-related events 
tend to occur over decades rather than over years, let alone 
months. Follow-up was stopped at 2 years in CLOSURE I which 
is vexing as longer follow-up could have been obtained in all 
patients. The first subject was enrolled on 23 June 2003 and the 
last one on 24 October 2008. Early procedural complications 
from PFO closure may be acceptable if there is a long-term 
reduction in recurrent stroke or drug-associated bleeds when 
compared with medical therapy alone. 
The PC trial (Percutaneous Closure of the Patent Foramen Ovale 
using the Amplatzer PFO Occluder compared to Medical Treat-
ment in Patients with Cryptogenic Embolism) randomly assigned 
414 adults <60 years of age with PFO and ischaemic stroke, TIA, 
or a peripheral embolic event to treatment with the Amplatzer 
PFO Occluder or medical therapy.(64) After a mean follow-up of 
4 years, the composite primary endpoint of death, nonfatal stroke, 
TIA, or peripheral embolism for the intention-to-treat cohort 
occurred in 7 of 204 patients (3.4%) in the device closure group 
and 11 of 210 patients (5.2%) in the medical therapy group (HR 
0.63, 95% CI 0.24-1.62, p=0.34). Similarly, results for the per-
protocol cohort showed that the difference between the groups 
was not statistically significant (HR 0.7, 95% CI 0.27-1.85, p=0.48).
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Nonfatal stroke occurred in 1 patient (0.5%) in the closure group 
and in 5 patients (2.4%) in the medical treatment group (HR 0.20, 
95% CI 0.02-1.74, p=0.14), and TIA occurred in 5 patients (2.5%) 
and 7 patients (3.3%), respectively (HR 0.71; 95% CI 0.23-2.24, 
P=0.56). Adverse events were slightly more frequent in the device 
closure group, including a nonsignificantly higher rate of new-onset 
atrial fibrillation in the device closure group (2.9 vs. 1.0%).
In the RESPECT trial (Randomised Evaluation of Recurrent Stroke 
Comparing PFO Closure to Established Current Standard of Care 
Treatment), 980 patients with a mean age of 46 years with a PFO 
and cryptogenic ischaemic stroke were randomly assigned to per-
cutaneous closure using the Amplatzer PFO Occluder or medical 
therapy.(65) The primary endpoint was a composite of recurrent 
nonfatal ischaemic stroke, fatal ischaemic stroke, or early death 
after randomisation. The trial results were analysed after reaching 
the preset target of 25 primary endpoint events, all of which 
nonfatal ischaemic strokes. Mean follow-up was 2.6 years. In the 
intention-to-treat cohort 9 of 499 patients (1.8%) in the closure 
group and 16 of 481 patients (3.3%) in the medical therapy group 
suffered a recurrent stroke. The difference was not statistically 
significant by time-to-event analysis (0.66 vs. 1.38 events per 100 
patient-years, HR 0.49, 95% CI 0.22-1.11, p=0.08). However, in the 
prespecified per-protocol cohort (944 patients who received the 
assigned treatment, adhered to the mandated medical treatment, 
and did not have a major inclusion or exclusion violation), the event 
rate was significantly lower for device closure, with 6 vs. 14 strokes 
(0.46 versus 1.3 events per 100 patient-years, HR 0.37, 95% CI 
0.14-0.96, p=0.03). Analysis for the prespecified as-treated cohort 
(958 patients who received a protocol-approved treatment, ad-
hered to the mandated medical treatment, and classified according 
to the treatment actually received) also showed a significant benefit 
for device closure (5 vs. 16 strokes, 0.39 vs. 1.45 events per 100 
patient-years, HR 0.27, 95% CI 0.10-0.75, p=0.007). Furthermore, 
percutaneous closure provided a significantly greater benefit in 
patients with severe right-to-left shunt at baseline (HR 0.18, 95% CI 
0.04-0-81, p=0.01), in those with an associated ASA (HR 0.19, 
95% CI 0.04-0.87, p=0.02), or when compared to those on anti-
platelet agents (HR 0.34, 95% CI 0.12-0.94, p=0.03). Recurrent 
strokes were larger in the medical treatment group (moderate, 
large, or massive infarcts in 9 out of 13 (69%) vs. 1 out of 7 (14%, 
p=0.06). There was no significant difference between the device 
closure and medical treatment groups in the rate of TIAs 
(HR 0.89, 95% CI 0.31-2.54, p=0.83), serious adverse events (23% 
vs. 21.6%, p=0.65), or the total incidence of atrial fibrillation (3.0 vs. 
1.5%, p=0.13).
Thus, with hazard ratios of 0.49 to 0.78, all 3 randomised trials 
suggested that PFO closure could be more effective than medical 
treatment alone for reducing event rates, but these results were 
not statistically significant by individual intention-to-treat analyses. 
An important shortcoming of all 3 trials is that the number of 
primary events was relatively low, with a total of 52 events in the 
CLOSURE I trial, 18 events in the PC trial, and 25 events in the 
RESPECT trial. Another issue concerns uneven dropout rates 
among both arms of these trials. Furthermore, follow-up in the 
CLOSURE I trial (2 years), the RESPECT trial (3 years), and even 
the PC trial (4 years) may not have been long enough to signifi-
cantly demonstrate benefit of closure.
There was no significant benefit for stroke risk reduction in several 
meta-analyses of the intention-to-treat data. Wolfrum, et al.(66) 
included a total of 14 studies (3 randomised controlled trials and 11 
non-randomised observational studies) with a total of 4 335 
patients. There was no significant treatment effect of PFO closure 
regarding stroke among the randomised controlled trials (HR 0.66, 
95% CI 0.37-1.19, p=0.171). However, among non-randomised 
studies stroke was reduced (HR 0.37, 95% CI 0.20-0.67, p<0.001) 
after PFO closure. A time-to-event (stroke) analysis, combining all 
3 randomised and the 2 non-randomised studies which applied 
strict multivariate adjustments, showed a borderline significant risk 
reduction after PFO closure (HR 0.58, 95% CI 0.33-0.99, p=0.047). 
Neither risk of bleeding nor mortality differed significantly between 
the groups. However, there was a higher incidence of new onset 
atrial fibrillation in the closure group (HR 3.50, 95% CI 1.47-8.35, 
p=0.005). There were signals pointing towards a potential benefit if 
non-randomised data or only randomised controlled trials using the 
Amplatzer PFO Occluder are considered.
Along with other meta-analyses,(67,68) Rengifo-Moreno, et al.(69) 
analysed the 3 randomised studies including a total of 2 303 
patients, with 1 150 patients randomised to PFO closure and 1 153 
patients randomised to medical therapy. Mean follow-up was 3.5 
years. Baseline characteristics (age, sex, and cardiovascular risk 
factors) were similar across studies. Intention-to-treat analyses 
showed a statistically significant risk reduction in stroke or TIA in 
the PFO closure group when compared to medical treatment 
(pooled HR 0.59, 95% CI 0.36-0.97, p=0.04). The combined 
outcome of death and vascular events showed a borderline 
statistically significant benefit for PFO closure when compared to 
medical treatment (pooled HR 0.67, 95% CI 0.44-1.00, p=0.05). 
Patients with a substantial interatrial shunt seemed to benefit the 
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most from PFO closure (pooled HR 0.35, 95% CI 0.12–1.03, 
p=0.06). However, this did not reach statistical significance.
The Gore Helex Septal Occluder and Antiplatelet Medical 
Management for Reduction of Recurrent Stroke or Imaging-
Confirmed TIA in Patients with Patent Foramen Ovale (REDUCE, 
NCT00738894), the Patent Foramen Ovale Closure or Anti-
coagulants Versus Antiplatelet Therapy to Prevent Stroke Recur-
rence (CLOSE, NCT00562289), and the Device Closure Versus 
Medical Therapy for Secondary Stroke Prevention in Cryptogenic 
Stroke Patients With High-Risk Patent Foramen Ovale (DEFENC-
PFO, NCT01552588) trials are ongoing. However, due to the fact 
that lower than expected event rates have to be anticipated, 
the included patient numbers and follow-up durations will likely 
again be insufficient to achieve satisfactory power.
As per potential long-term hazards, device endocarditis represents 
a problem reported in a few case reports but not encountered in 
our experience. The device may embolise peri-procedurally but it 
should then be amenable to percutaneous retrieval in most cases. 
Late device embolisation is hardly possible. Arm fractures were 
reported for some obsolete devices, but not with Amplatzer 
occluders. Late atrial fibrillation may occur but a causal relationship 
to the device will be difficult to establish.
CONCLUSION
Despite the availability of the results of the long awaited first 
3 randomised controlled trials, the optimal treatment strategy for 
patients with documented or suspected paradoxical embolism 
remains controversial. These results did not change many minds. 
The sceptics saw themselves confirmed by 3 negative randomised 
controlled studies. Those believing in the rationale for PFO closure 
were encouraged by the substantial albeit nonsignificant relative 
risk reduction of recurrent strokes (significant in the prespecified 
subgroups of patients with large shunts or ASA, or in all when 
compared to treatment with acetylsalicylic acid only), and the 
positive per-protocol and as-treated analyses of the RESPECT 
trial. It can be assumed that adding a couple more years to 
the protocol-based follow-up duration of the PC and the 
RESPECT trials will render them individually significant. Indeed, a 
non-randomised but propensity score matched analysis of a 
Bern cohort with long-term follow-up (median 9 years) showed 
a significant reduction of the primary composite outcome of 
stroke, TIA, or peripheral embolism and even a mortality benefit 
when analysed per treatment status. 
Moreover, the PC and RESPECT trials promise an extended follow-
up of their patients in addition to a continued analysis on patient-
data basics. That might be quite compelling.
Percutaneous PFO closure is a minimally invasive procedure which 
can be performed with high success and low morbidity. With 
respect to secondary prevention of recurrent embolic events, 
percutaneous PFO closure appears to be clinically at least as 
effective as medical treatment without the risk of long term 
anticoagulation which should be with a vitamin K antagonist or 
perhaps a direct oral anticoagulant according to the RESPECT trial 
subanalysis. The overall safety profile of Amplatzer Occluders 
appears to be superior to that of other devices, especially the now 
defunct STARFlex occluder. While one can argue that closure 
cannot be presented as the recommended treatment, it should at 
least be mentioned as an attractive option. It has been referred 
to as a once-in-a-lifetime mechanical vaccination compared to 
lifelong medical treatment. However, one has to be reminded that 
the prevalence of PFO in the general population is high (~25%) 
and so discovering one, even in a patient with cryptogenic stroke, 
does not per se prove paradoxical embolism. The Risk of Para-
doxical Embolism (RoPE) study has shown that there are baseline 
patient characteristics that can predict whether a discovered PFO is 
likely to be pathogenic or incidental.(70) The scale unfortunately is 
built on the shaky ground that a PFO is the last of all stroke causes 
to be considered. Closing an incidental PFO is not going to prevent 
non-PFO-related stroke recurrence while exposing the patient to 
some, however small, procedural and device risks.
Declaration: Bernhard Meier has received research 
grants to the institution and personal speaker fees from 
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